Health & Biotech
Respiri Limited (ASX: RSH) are an Australian owned company with smart tools to empower people with asthma and improve outcomes.
Backed by over twenty years of research by respiratory specialists, and with first-move advantage, Respiri offers an over-the-counter monitoring solution that will help people manage asthma in ways that have never been available before.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Pharmacists to begin recommending Respiri’s wheezo asthma management device
Health & Biotech
Respiri rolls out wheezo device distribution with Pharmacy 4 Less group
Health & Biotech
Telehealth in 2021: What will change and will a COVID-19 vaccine stop the sector’s growth?
Health & Biotech
Respiri reasserts full-year revenue guidance after locking in key product order, shares climb
News
Last Orders: What you might have missed on the ASX today
Health & Biotech
Respiri details ‘exceptional’ cost savings to wheezo production
Health & Biotech
Initial interest for Respiri’s asthma management wheezo device ‘exceeding expectations’
Health & Biotech
Respiri takes steps to secure intellectual property with another patent filing
Health & Biotech
Investors line up to give Respiri cash as wheezo launches into Australian pharmacies
Health & Biotech
ASX asthma stocks: Global Health becomes the latest contender
Health & Biotech
Respiri finds cheaper production partner for asthma management device
Health & Biotech
Here’s what the telehealth industry wants from ScoMo to maintain momentum
Health & Biotech
Respiri clinical trial shows ‘substantial agreement’ with doctor stethoscope test for asthma detection
Health & Biotech
Respiri catches a screamer with Carlton AFLW deal
Health & Biotech
APA in deal to sell Respiri’s wheezo to members
Stockhead TV
StockTalk: How are ASX medtechs responding to skyrocketing healthcare spending?
Health & Biotech